News | November 14, 2021
Alarming rise in diabetes amongst children and adolescents in India
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The start-up has announced the scheme to mark World Diabetes Day
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Acute therapies continue to report strong growth compared to chronic ones.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The company claims that its Empagliflozin tablets are the most affordable in India
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The company plans to expand its portfolio in regulated markets aggressively
Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Subscribe To Our Newsletter & Stay Updated
